tbuckley/cabot-search huggingface dataset:
Abstract 18468: Low Dose Anticoagulation is Safe and Feasible After Isolated Mechanical Aortic Valve Replacement With Livanova Prosthesis
Authors: Michele Torella, Daniele Torella, Paolo Chiodini, Cristiano Amarelli, Marisa De Feo, Alessandro Della Corte, Giampaolo Romano, Luca Salvatore De Santo
Journal: Circulation (2017)

Introduction: Thrombotic complications are due to a complex interplay between patients’ features, device characteristics, and anticoagulation intensity. Low-dose anticoagulation is safe and feasibl...
Stress-induced epinephrine enhances lactate dehydrogenase A and promotes breast cancer stem-like cells
Authors: Bai Cui, Yuanyuan Luo, Pengfei Tian, Fei Peng, Jinxin Lu, Yongliang Yang, Qitong Su, Bing Liu, Jiachuan Yu, Xi Luo, Liu Yin, Wei Cheng, Fan An, Bin He, Dapeng Liang, Sijin Wu, Peng Chu, Luyao Song, Xinyu Liu, Huandong Luo, Jie Xu, Yujia Pan, Yang Wang, Dangsheng Li, Peng Huang, Qingkai Yang, Lingqiang Zhang, Binhua P. Zhou, Suling Liu, Guowang Xu, Eric W.-F. Lam, Keith W. Kelley, Quentin Liu
Journal: Journal of Clinical Investigation (2019)

Chronic stress triggers activation of the sympathetic nervous system and drives malignancy. Using an immunodeficient murine system, we showed that chronic stress-induced epinephrine promoted breast cancer stem-like properties via lactate dehydrogenase A-dependent (LDHA-dependent) metabolic rewiring. Chronic stress-induced epinephrine activated LDHA to generate lactate, and the adjusted pH directed USP28-mediated deubiquitination and stabilization of MYC. The SLUG promoter was then activated by MYC, which promoted development of breast cancer stem-like traits. Using a drug screen that targeted LDHA, we found that a chronic stress-induced cancer stem-like phenotype could be reversed by vitamin C. These findings demonstrated the critical importance of psychological factors in promoting stem-like properties in breast cancer cells. Thus, the LDHA-lowering agent vitamin C can be a potential approach for combating stress-associated breast cancer.
Diffuse-Type Tenosynovial Giant Cell Tumor of the Shoulder Evaluated by FDG PET/CT
Authors: Kun Tang, Xiangwu Zheng, Jie Lin, Ling Wang
Journal: Clinical Nuclear Medicine (2019)

Diffuse-type tenosynovial giant cell tumor is a locally aggressive neoplasm that typically involves the knee and hip but rarely involves the shoulder. In this case, a 74-year-old woman presented a painless mass in the right shoulder. FDG PET/CT demonstrated intense FDG uptake with an SUVmax of 19.2 in the lesion. The mass was dissected and confirmed as diffuse-type tenosynovial giant cell tumor by pathology. Follow-up FDG PET/CT assessment revealed more extensive soft tissue infiltration and adjacent bone erosion 3 years after surgery. Thus, FDG PET/CT well demonstrated the hypermetabolic and local aggressive characteristics of the lesion.
Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival
Authors: AGM Mostofa, Allison Distler, Mark B. Meads, Eva Sahakian, John J. Powers, Tuan Nguyen, Melissa Alsina, Taiga Nishihori, Rachid Baz, Javier Pinilla Ibarz, Eduardo Sotomayor, Kenneth H. Shain, Jason B. Brayer
Journal: Blood (2018)
Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas
Authors: Ho-Young Yhim, Yong Park, Joon Ho Moon, Ho-Jin Shin, Yoon Seok Choi, Min Kyoung Kim, Dae Sik Kim, Ji Hyun Lee, Won Sik Lee, Young Rok Do, Jun Soo Ham, Seok Jin Kim, Won Seog Kim, Deok-Hwan Yang, Jae-Yong Kwak
Journal: Blood (2018)
Abstract 15378: The Association of First Responder Response Time and Outcomes in Out-of-Hospital Cardiac Arrest
Authors: Guillaume Geri, Laurie J Morrison, Peter C Austin, Paul Dorian, Sheldon Cheskes, Michael Feldman, Jason E Buick, Ian R Drennan, Timothy C Chan, Richard Verbeek, Dennis T Ko
Journal: Circulation (2017)

Background: Although it is commonly believed that minimizing treatment times is beneficial for patients with out-of-hospital cardiac arrest (OHCA), few studies have evaluated the importance of resp...
Bronchial hyperresponsiveness in patients with local allergic rhinitis and lower airway symptoms
Authors: Paloma Campo, Maria Salas, Ibon Eguiluz-Gracia, Gador Bogas, Esther Barrionuevo, Beatriz de Julián, Teresa Espino, MD Cañamero, M.J. Torres, Carmen Rondon
Journal: Journal of Allergy and Clinical Immunology (2019)
Abstract 12255: Up to Seven-Year Outcomes After Transcatheter Pulmonary Valve Replacement in the Prospective Multicenter US Melody Valve Investigational Device Exemption Trial
Authors: John P Cheatham, Julie A Vincent, Evan M Zahn, Lisa Bergersen, Darren P Berman, James E Lock, William E Hellenbrand, Thomas K Jones, Doff B McElhinney
Journal: Circulation (2014)

Introduction: Transcatheter pulmonary valve replacement (TPVR) with the Melody valve was introduced in the US in 2007 through the Investigational Device Exemption (IDE) trial. Although earlier Euro...
Abstract 17890: High Perforin-Positive Cardiac Cell Infiltration and Male Gender Predict Adverse Long-Term Mortality in Patients With Inflammatory Cardiomyopathy
Authors: Felicitas Escher, Dirk Lassner, Uwe Kuehl, Burkert Pieske, Wolfgang Poller, Heinz-Peter Schultheiss
Journal: Circulation (2017)

Aims: We analysed possible influence of perforin-dependent infiltration upon long-term mortality in patients with inflammatory cardiomyopathy (CMi). We previously demonstrated that left ventricular...
PRMT1 Mediated FLT3 Methylation As a Therapeutic Vulnerability in FLT3-ITD+ AML
Authors: Xin He, Yinghui Zhu, Haojie Dong, Sierra Min Li, Zonghui Ding, Jie Sun, Juan Du, Hanying Wang, Lianjun Zhang, Yudao Shen, Hairui Su, Samer K. Khaled, Dandan Zhao, Lei Zhang, Robert Hickey, Bin Zhang, Ya-Huei Kuo, Xinyang Zhao, Jian Jin, Nadia Carlesso, Jianjun Chen, Yang Xu, Guido Marcucci, Ling Li
Journal: Blood (2018)
Abstract 20245: Specific Intracellular Glycosylation Directly Modulates CaMKII Activity During Hyperglycemia
Authors: Jeffrey Erickson, Ruchi Patel, Gerald Hart, Donald Bers
Journal: Circulation (2010)

GlcNAcylation, a post-translational modification in which an O-GlcNAc moiety is added to a serine or threonine residue, is emerging as an important regulator of protein function. Though O-GlcNAc mo...
Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.
Authors: Julien Taieb, Timothy Jay Price, Fortunato Ciardiello, Marc Peeters, Lucjan Wyrwicz, Jean-Baptiste Bachet, Christophe Borg, Christelle De La Fouchardiere, Martin Becquart, Nadjat Mounedji, Loïck Vidot, Javier Sabater, Alfredo Falcone
Journal: Journal of Clinical Oncology (2019)

638 Background: Pivotal RECOURSE trial assessed efficacy and safety of trifluridine/tipiracil (FTD/TPI) in mCRC patients (pts) without collecting QoL data. Here we describe a preliminary analysis of QoL in mCRC pts treated with FTD/TPI in the ongoing phase 3b PRECONNECT study (NCT03306394). Methods: Eligible pts had histologically mCRC previously treated with available therapies and an ECOG-PS of 0/1. Pts received FTD/TPI (35 mg/m 2 twice daily) orally on days 1–5 and 8–12 of each 28-day cycle. ECOG-PS and QoL were assessed at baseline, every 4 weeks on FTD/TPI and at discontinuation. QoL was measured with EORTC QLQ-C30, EQ-5D index and VAS questionnaires. Utility score was based on EQ-5D index and values from Germany, UK and Spain. For QLQ-C30, clinical relevance was assessed using a 10 point threshold. Changes in utility score and VAS were deemed clinically relevant if ≥ 9 and ≥ 7, respectively. Only results where ≥ 10% of the initial cohort completed the questionnaires were assessed, corresponding to 7 cycles of treatment. Results: 464 pts were included at cutoff (1 November 2017). Median FTD/TPI treatment duration was 2.96 months (range 0.4–14.7). Median time to ECOG-PS ≥ 2 was 8.7 months with 74.3% of pts remaining at ECOG-PS 0/1 at discontinuation. At baseline mean QLQ-C30 global health status was 62.75 (SD = 20.50; median 66.67) with values for all scales in line with EuroQoL reference for mCRC (variation &lt; 10 points on function and &lt; 5 on symptom scales). Baseline EQ-5D VAS was 65.55 (SD = 20.11; median 70.00) and utility score 73.11 (SD = 20.71; median 75.27). There was no clinically relevant difference in mean change from baseline at any time point on global health status score nor any of functional or symptom scales. Similar results were obtained for utility score and VAS. QoL was maintained on FTD/TPI in all subgroups based on age and ECOG-PS for all scales except for appetite loss increase at cycle 5 in pts ≥ 65 and in ECOG-PS 0 in whom the score increased by 12.2 and 10.4, respectively. Conclusions: The first prospective data on QoL suggest that mCRC pts can maintain their QoL while on FTD/TPI treatment. Clinical trial information: NCT03306394.
Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS
Authors: Cassandra M. Hirsch, Wenyi Shen, Bartlomiej P. Przychodzen, Yasunobu Nagata, Vera Adema, Teodora Kuzmanovic, Louis Williams, Aziz Nazha, Valeria Visconte, Hetty E. Carraway, Mikkael A. Sekeres, Jaroslaw P. Maciejewski
Journal: Blood (2018)
Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
Authors: Constant V.M. Verschuur, Sven R. Suwijn, Judith A. Boel, Bart Post, Bas R. Bloem, Johannes J. van Hilten, Teus van Laar, Gerrit Tissingh, Alexander G. Munts, Guenther Deuschl, Anthony E. Lang, Marcel G.W. Dijkgraaf, Rob J. de Haan, Rob M.A. de Bie
Journal: New England Journal of Medicine (2019)

Levodopa is the main treatment for symptoms of Parkinson's disease. Determining whether levodopa also has a disease-modifying effect could provide guidance as to when in the course of the disease the treatment with this drug should be initiated.In a multicenter, double-blind, placebo-controlled, delayed-start trial, we randomly assigned patients with early Parkinson's disease to receive levodopa (100 mg three times per day) in combination with carbidopa (25 mg three times per day) for 80 weeks (early-start group) or placebo for 40 weeks followed by levodopa in combination with carbidopa for 40 weeks (delayed-start group). The primary outcome was the between-group difference in the mean change from baseline to week 80 in the total score on the Unified Parkinson's Disease Rating Scale (UPDRS; scores range from 0 to 176, with higher scores signifying more severe disease). Secondary analyses included the progression of symptoms, as measured by the UPDRS score, between weeks 4 and 40 and the noninferiority of early initiation of treatment to delayed initiation between weeks 44 and 80, with a noninferiority margin of 0.055 points per week.A total of 445 patients were randomly assigned: 222 to the early-start group and 223 to the delayed-start group. The mean (±SD) UPDRS score at baseline was 28.1±11.4 points in the early-start group and 29.3±12.1 points in the delayed-start group. The change in UPDRS score from baseline to week 80 was -1.0±13.1 points and -2.0±13.0 points, respectively (difference, 1.0 point; 95% confidence interval [CI], -1.5 to 3.5; P=0.44); this finding of no significant between-group difference at week 80 implies that levodopa had no disease-modifying effect. Between weeks 4 and 40, the rate of progression of symptoms, as measured in UPDRS points per week, was 0.04±0.23 in the early-start group and 0.06±0.34 in the delayed-start group (difference, -0.02; 95% CI, -0.07 to 0.03). The corresponding rates between weeks 44 and 80 were 0.10±0.25 and 0.03±0.28 (difference, 0.07; two-sided 90% CI, 0.03 to 0.10); the difference in the rate of progression between weeks 44 and 80 did not meet the criterion for noninferiority of early receipt of levodopa to delayed receipt. The rates of dyskinesia and levodopa-related fluctuations in motor response did not differ significantly between the two groups.Among patients with early Parkinson's disease who were evaluated over the course of 80 weeks, treatment with levodopa in combination with carbidopa had no disease-modifying effect. (Funded by the Netherlands Organization for Health Research and Development and others; LEAP Current Controlled Trials number, ISRCTN30518857 .).
Microrna-130a Regulates Hematopoietic Stem Cell Self-Renewal By Repressing Chromatin Modifiers and Shaping the Accessible Chromatin Landscape
Authors: Gabriela Krivdova, Schoof E Erwin, Veronique Voisin, Alex Murison, Karin G. Hermans, Laura Garcia Prat, Olga I. Gan, Elvin Wagenblast, Aaron Trotman-Grant, Eric R. Lechman,, Mark D. Minden, John E. Dick
Journal: Blood (2018)
Case Volume and Outcomes After TAVR With Balloon-Expandable Prostheses
Authors: Mark J. Russo, James M. McCabe, Vinod H. Thourani, Mayra Guerrero, Philippe Genereux, Tom Nguyen, Kimberly N. Hong, Susheel Kodali, Martin B. Leon
Journal: Journal of the American College of Cardiology (2019)

Given conflicting findings of previous studies, much remains to be understood regarding a volume-outcomes relationship (VOR) in transcatheter aortic valve replacement (TAVR). The purpose of this study was: 1) to determine if, after the initial learning curve (LC), a VOR for balloon-expandable (BE) TAVR persisted; and 2) to determine if LCs and VORs differed across different device generations. Data collected by the TVT registry for BE valve implants from November 2011 through January 2017 were included in this analysis (n = 61,949). Primary outcomes included 30-day all-cause mortality, stroke, and major vascular complications. For each center, all implants were ordered chronologically according to case sequence number (CS#). To determine where the learning curve terminated (LCT), a grid search analysis was applied across a range of CS# from 10 to 300 by increments of 1. After LCT, the VOR was assessed by examining case volume/month by center. This analysis was performed separately for: 1) all BE valve types; 2) Sapien 3 (S3) only; and 3) S3 in BE valve naïve sites. In experience with all commercially available BE valve types, there was an initial LC that terminates around case #201. After the initial LC, a volume–outcomes relationship was no longer evident. In analysis limited to S3, there was no demonstrable LC or VOR. Likewise, there was no demonstrable LC or VOR with S3 for BE valve naïve sites. After a case experience of 200 cases, there was LCT; subsequent to initial learning, a VOR was no longer evident. In the S3-only analysis, there was no LC or no demonstrable VOR. With current-generation BE-TAVR, centers should expect to achieve consistently excellent outcomes even during early case experience.
Abstract MP029: Sleep Duration and Sedentary Behavior as Predictors of Cardiovascular Disease in Mid-Life
Authors: Coles Hoffmann, Megan E Petrov, Mary C Davis, Alex J Zautra
Journal: Circulation (2017)

Introduction: Sedentary behavior and short sleep duration are independently associated with cardiovascular disease (CVD), but there is limited research on the interaction between sedentary behavior and sleep duration on CVD. Hypothesis: Short sleep duration combined with greater sedentary behavior will be significantly associated with CVD. Methods: Middle-aged (40-65), community-dwelling adults were recruited to participate in a healthy aging study. Participants completed questionnaires on demographics, medical history, and habitual sleep duration. Sleep duration was categorized as &lt; 6 vs. ≥ 6 hours. Sedentary behavior, measured with the International Physical Activity Questionnaire, was defined as sitting in hours/day dichotomized at the 75 th percentile (&lt; 9 vs. ≥ 9 hrs). CVD was defined as reported diagnosis of one or more of five conditions including coronary artery disease, congestive heart failure, myocardial infarction, arrhythmias, and stroke. Of the total sample of 770 individuals, 731 who had complete data on sleep, sitting, and CVD were included in the analysis. We conducted logistic regression models predicting CVD from sleep duration and sitting time groups adjusting sequentially for demographics (age, sex, education level) and CVD risk factors (reported high blood pressure and diabetes) (see Table). Results: CVD was present in 21% of the sample (n = 162). Participants who reported &lt; 6 hrs sleep duration and sitting &lt; 9 hrs/day were at significantly greater risk for CVD events compared to participants obtaining ≥ 6 hrs sleep duration and sitting &lt; 9 hrs/day in the demographic model (see Table). Adjustment for CVD risk factors attenuated the relationship to borderline significance. Conclusions: Contrary to prediction, short sleep duration combined with short to moderate sitting time was associated with CVD events. Interpretation of the results should be done cautiously given our analysis was limited by a small sample size and a lack of adjustment for other potential CVD risk factors.
Evaluation of Cord Blood (CB) Unit TNC &amp; CD34+ Cell Content &amp; Donor-Recipient High-Resolution 8 HLA-Allele Match By Patient Ancestry: An Evaluation of 513 CB Units in a Racially &amp; Ethnically Diverse Population of Adults with Hematologic Malignancies
Authors: Christopher Mazis, Ioannis Politikos, Sean M Devlin, Molly Maloy, Eric Davis, Candice Cooper, Melissa Nhaissi, Beth Suri, Deborah Wells, Sergio Giralt, Gunjan L. Shah, Marcel R.M. van den Brink, Nancy A. Kernan, Andromachi Scaradavou, Juliet Barker
Journal: Blood (2018)
Correlations between Alt a 1 concentrations, Alternaria alternata and Pleasporaceae measured by molecular methods in New York City house dust
Authors: Hadler A. daSilva, Adnan Divjan, Karen C. Dannemiller, Luis M. Acosta, Rachel L. Miller, Brett J. Green, Matthew S. Perzanowski
Journal: Journal of Allergy and Clinical Immunology (2019)
A Framework for Increasing Trust Between Patients and the Organizations That Care for Them
Authors: Thomas H. Lee, Elizabeth A. McGlynn, Dana Gelb Safran
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.
Authors: Janet E. Murphy, Leilana Ly, Jennifer Yon-Li Wo, David P. Ryan, Jeffrey W. Clark, Beow Y Yeap, Lorraine C. Drapek, Lawrence Scott Blaszkowsky, Aparna Raj Parikh, Ryan David Nipp, Eunice Lee Kwak, Jill N. Allen, Ryan Bruce Corcoran, Jason Edward Faris, Andrew X. Zhu, Lipika Goyal, Thomas F. DeLaney, Cristina Ferrone, Carlos Fernandez-del Castillo, Colin D. Weekes
Journal: Journal of Clinical Oncology (2019)

392 Background: Optimal timing and duration of FFX for resectable, borderline resectable, and LAPC has not been established. The PRODIGE 24/CCTG PA.6 study used 12 cycles of adjuvant modified FFX (eliminating bolus 5FU, irinotecan at 150mg/m2) demonstrating superior DFS (21.6 mo) over gemcitabine (12.8 mo). However, only 48% of patients (pts) received 70% of intended chemo dosing, and 66.4% of pts completed all doses due to postoperative tolerability. We conducted total neoadjuvant therapy (TNT) studies in borderline and LAPC. (LAPC study included Losartan experimentally.) Dose intensity of TNT with FFX is compared to the benchmark adjuvant data. Methods: In this retrospective analysis, chemotherapy data were analyzed from NCT01821729 (LAPC) and NCT01591733 (Borderline). Both studies included 8 cycles of neoadjuvant FFX: b5FU 400mg/m2, CI 5U 1200mg/m2/d x 2d, oxaliplatin 85mg/m2, and irinotecan 180mg/m2. Results: 92 pts were studied: Borderline n = 43, LAPC n = 49. Sixteen of 92 (17.3%) patients discontinued chemotherapy prior to 8 cycles due to: withdrawal of consent (2), chemotherapy toxicity (6), progression (4), and disease-related complications (4). 82.6% of patients completed 8 doses. 61.4% of all bFU was given at the intended dose of 400 mg/m2. The mean relative dose intensity of b5FU (the actual cumulative dose relative to the planned cumulative dose over 8 cycles) was 72%. 65.5% of patients required a reduction in b5FU over eight cycles. Data for all chemotherapy are presented in Table 1. Overall, 71 of 92 patients (77.2%) had &gt; 70% dose of FFX, with mean relative dose intensity of 81.2%. Among surgically resected patients, mPFS was 21.3 months in LAPC (n = 34) and 48.6 months in Borderline (n = 33). Conclusions: Compared to adjuvant therapy, dose intensity was achieved in a higher proportion of participants with TNT, utilizing a FFX regimen that included b5FU and irinotecan at 180mg/m2. PFS among resected patients reflects this highly active treatment. [Table: see text]
TCR Repertoire Analysis Reveals Public Motifs with High Probability for Allergen Epitope Specificity
Authors: Neal P. Smith, Bert Ruiter, Navneet K. Virk Hundal, Huong G. Tang, Yamini V. Virkud, Sarita U. Patil, Wayne G. Shreffler
Journal: Journal of Allergy and Clinical Immunology (2019)
Abstract 14855: Differential Prognostic Impact of Anemia in 75 Years or Older Male and Female Patients With Heart Failure With Preserved Ejection Fraction: Analysis of Japanese Heart Failure Syndrome With Preserved Ejection Fraction (JASPER) Study
Authors: Keisuke Okuno, Yoshiro Naito, Masanori Asakura, Masataka Sugahara, Tomotaka Ando, Toshiyuki Nagai, Yoshihiko Saito, Tsutomu Yoshikawa, Tohru Masuyama, Toshihisa Anzai
Journal: Circulation (2017)

Introduction: Anemia is common and is associated with poor prognosis in patients with heart failure (HF). The prognostic impact of anemia was reported in patients with HF with preserved ejection fr...
The Persistence of Metaphor
Authors: Jack Coulehan
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal